Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer
NCT ID: NCT01476111
Last Updated: 2015-03-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
117 participants
OBSERVATIONAL
2011-12-31
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
NCT02338531
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
NCT05916755
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
NCT00455533
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
NCT05681728
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
NCT01276769
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Patients with primary invasive breast cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient has provided pre-treatment tumor samples for WT1 expression screening and gene expression profiling in the context of the NCT01220128 study.
* The patient has a histologically or cytologically confirmed primary invasive breast cancer.
* The patient has provided written informed consent before any new information or new material is provided to the Sponsor.
* The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.
* The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Newark, Delaware, United States
GSK Investigational Site
Plantation, Florida, United States
GSK Investigational Site
Charleston, South Carolina, United States
GSK Investigational Site
Amarillo, Texas, United States
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Namur, , Belgium
GSK Investigational Site
Tübingen, Baden-Wurttemberg, Germany
GSK Investigational Site
Erlangen, Bavaria, Germany
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany
GSK Investigational Site
Dortmund, North Rhine-Westphalia, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Homburg, Saarland, Germany
GSK Investigational Site
Chemnitz, Saxony, Germany
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany
GSK Investigational Site
Napoli, Campania, Italy
GSK Investigational Site
Aviano (PN), Friuli Venezia Giulia, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Pavia, Lombardy, Italy
GSK Investigational Site
Turin, Piedmont, Italy
GSK Investigational Site
Ryazan, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Bournemouth, , United Kingdom
GSK Investigational Site
Derby, , United Kingdom
GSK Investigational Site
Edinburgh, , United Kingdom
GSK Investigational Site
Nottingham, , United Kingdom
GSK Investigational Site
Poole, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
115400
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.